All In Biotech

Drug Trial Radar · NCT01763164

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma

Last checked: Nov 19, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

402

Actual

Start

Jul 12, 2013

Primary completion

Dec 1, 2015

Study completion Jun 4, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival

Conditions

  • Metastatic or Unresectable Cutaneous Melanoma

Interventions

  • MEK162Drug

    MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.

  • DacarbazineDrug

    Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)

Locations

229 sites in 27 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Highlands Oncology Group

    Rogers, Arkansas

  • Florida Cancer Specialists

    Altamonte Springs, Florida

  • Florida Cancer Specialists

    Bonita Springs, Florida

  • Florida Cancer Specialists

    Bradenton, Florida

  • Florida Cancer Specialists

    Brandon, Florida

  • Florida Cancer Specialists

    Cape Coral, Florida

  • Florida Cancer Specialists

    Clearwater, Florida

  • Florida Cancer Specialists

    Clearwater, Florida

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Florida Cancer Specialists

    Gainesville, Florida

  • Florida Cancer Specialists

    Hudson, Florida

  • Florida Cancer Specialists

    Inverness, Florida

  • Florida Cancer Specialists

    Largo, Florida

  • Florida Cancer Specialists

    Largo, Florida

  • Florida Cancer Specialists

    Naples, Florida

  • Florida Cancer Specialists

    Naples, Florida

  • Florida Cancer Specialists

    New Port Richey, Florida

  • Florida Cancer Specialists

    Orange City, Florida

  • Florida Cancer Specialists

    Orlando, Florida

  • Florida Cancer Specialists

    Port Charlotte, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • Florida Cancer Specialists

    Spring Hill, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • Florida Cancer Specialists

    Tampa, Florida

  • Florida Cancer Specialists

    Tampa, Florida

  • Florida Cancer Specialists

    Tavares, Florida

  • Florida Cancer Specialists

    Venice, Florida

  • Florida Cancer Specialists

    Venice, Florida

  • Oncology Specialists, SC

    Niles, Illinois

  • Oncology Specialists, SC

    Park Ridge, Illinois

  • Goshen Center For Cancer Care

    Goshen, Indiana

  • Eastern Maine Medical Center

    Bangor, Maine

  • Harry and Jeannette Weinberg Cancer Institute @Franklin Square

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

Showing 40 of 229 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.